Nexalin Technology (NXL) Investor presentation summary

Market overview and unmet needs

• Mental health disorders such as insomnia, anxiety, depression, Alzheimer's, and PTSD affect over 1.9 billion people globally, representing a $60 billion and growing market opportunity.

• Current drug and non-invasive neurostimulation treatments have low efficacy, significant side effects, and high rates of patient dissatisfaction, with 70% preferring drug-free alternatives.

Technology and clinical validation

• Deep Intracranial Frequency Stimulation (DIFS®) delivers a proprietary, undetectable waveform with 15x the power of existing neurostimulators, enabling deeper brain penetration and higher efficacy without discomfort or side effects.

• Clinical validation includes 33 trials (13 international, 7 with neuroimaging), with published data supporting efficacy in insomnia, depression, Alzheimer's, and PTSD.

• Internal and published data show significant improvements in cognitive function and brain activity for Alzheimer's and dementia patients.

Product pipeline and regulatory status

• Three generations: Gen 1 (clinic-based, FDA-cleared for anxiety, depression, insomnia), Gen 2 SYNC (in-clinic, deeper penetration, regulatory approvals in Asia, Brazil, Middle East, Israel), Gen 3 HALO (at-home, virtual clinic, FDA application expected 2026).

• Gen 3 HALO enables remote, physician-monitored treatment, with patients self-administering therapy at home via a digital ecosystem.

• Ongoing and planned FDA clinical trials in the US for insomnia, Alzheimer's, dementia, TBI, PTSD, depression, and future expansion to anxiety, addiction, and chronic pain.